EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications

Larisa H Cavallari, James C Coons

Interventional Cardiology Clinics · 2024

DOI: 10.1016/j.iccl.2024.06.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Interventional Cardiology Clinics, 2024. Verfasst von Larisa H Cavallari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, 1333 Center Driv…. Hauptthemen laut MEDLINE: Purinergic P2Y Receptor Antagonists, Cytochrome P-450 CYP2C19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CYP2C19 enzyme metabolizes clopidogrel, a prodrug, to its active form. Approximately 30% of individuals inherit a loss-of-function (LoF) polymorphism in the CYP2C19 gene, leading to reduced formation of the active clopidogrel metabolite. Reduced clopidogrel effectiveness has been well documented in patients with an LoF allele following an acute coronary syndrome or percutaneous coronary intervention. Prasugrel or ticagrelor is recommended in those with an LoF allele as neither is affected by CYP2C19 genotype. Although data demonstrate improved outcomes with a CYP2C19-guided approach to P2Y12 inhibitor selection, genotyping has not yet been widely adopted in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purinergic P2Y Receptor AntagonistsCytochrome P-450 CYP2C19HumansAcute Coronary SyndromeClopidogrelPercutaneous Coronary InterventionGenotypeTicagrelorPlatelet Aggregation InhibitorsPrasugrel HydrochloridePolymorphism, Genetic

Stichwörter der Autor:innen

CYP2C19ClopidogrelGenotypePharmacogenomicsPrasugrelTicagrelor

Substanzen

Purinergic P2Y Receptor AntagonistsCytochrome P-450 CYP2C19CYP2C19 protein, humanClopidogrelTicagrelorPlatelet Aggregation InhibitorsPrasugrel Hydrochloride

Autor:innen und Institutionen

  • Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, 1333 Center Drive, PO Box 100486, Gainesville, FL 32610, USA. Electronic address: lcav…
  • Department of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh, 9058 Salk Hall, 3501 Terrace Street, Pittsburgh, PA 15261, USA.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Cavallari, L. H., & Coons, J. C. (2024). Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications. Interventional Cardiology Clinics. https://doi.org/10.1016/j.iccl.2024.06.002

Vancouver

Cavallari LH, Coons JC. Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications. Interventional Cardiology Clinics. 2024. doi:10.1016/j.iccl.2024.06.002

BibTeX
@article{Cavallari2024,
  author = {Cavallari, Larisa H and Coons, James C},
  title = {Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications},
  journal = {Interventional Cardiology Clinics},
  year = {2024},
  doi = {10.1016/j.iccl.2024.06.002}
}
Kostenlos starten →